NCT00025220View on ClinicalTrials.gov

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2003

Study Completion Date

July 31, 2008

Conditions
Recurrent Uterine Corpus SarcomaUterine Corpus Leiomyosarcoma
Interventions
DRUG

Thalidomide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00025220 - Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Biotech Hunter | Biotech Hunter